9979, Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Protocol: 
AAAR2852
Phase: 
I

9979, Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Are you Eligible? (Inclusion Criteria)

1) Subjects must have histologically confirmed malignancy with brain
metastases and are
being evaluated for palliative WBRT.

2) Subjects must not have received systemic cytotoxic chemotherapy or
immunotherapy for
3 weeks before initiation of therapy.

3) Age ≥ 18 years.

Specialty Area(s)